Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies-Reference-Cited by-同舟云学术

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies

Published:2018-12-01 Issue:3 Volume:7 Page:LMT07
ISSN:1758-1966
Container-title:Lung Cancer Management
language:en
Short-container-title:Lung Cancer Management

Author:

Arasanz Hugo¹²,Zuazo Miren¹,Vera Ruth²,Kochan Grazyna¹,Escors David¹³

Affiliation:

1. Immunomodulation Group, Navarrabiomed-Fundación Miguel Servet, IdISNA, Complejo Hospitalario de Navarra (CHN), Irunlarrea 3, 31008 Pamplona, Navarra, Spain

2. Department of Oncology, Complejo Hospitalario de Navarra (CHN), Irunlarrea 3, 31008 Pamplona, Navarra, Spain

3. Division of Infection & Immunity, Rayne Institute, University College London, 5 University Street, London WC1E 6JF, UK

Publisher

Future Medicine Ltd

Subject

Pulmonary and Respiratory Medicine,Oncology

Link

https://www.futuremedicine.com/doi/pdf/10.2217/lmt-2018-0014

Reference17 articles.

1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial

2. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

3. Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

4. Hyperprogressive disease: recognizing a novel pattern to improve patient management

5. Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Resistance to PD-L1/PD-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?;Frontiers in Pharmacology;2020-04-07